文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

下消化道出血风险评分比较:系统评价与Meta分析

Comparison of Risk Scores for Lower Gastrointestinal Bleeding: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Netw Open · 2022-05-02
一句话结论Oakland评分预测安全出院、大出血和输血需求区分度最佳,Strate评分预测止血需求最佳;作者认为这些评分可用于预测下消化道出血结局并指导临床。

该研究系统检索1990年1月1日至2021年8月31日Ovid MEDLINE、Embase和Cochrane对照试验中心注册库,纳入9项研究、12个独立队列、4种下消化道出血风险评分(Oakland、Strate、NOBLADS、BLEED),采用随机效应模型合并诊断性能指标。预测安全出院时Oakland评分AUROC为0.86(95%CI 0.82-0.88);预测大出血时Oakland评分AUROC为0.93(95%CI 0.90-0.95),优于Strate 0.73、NOBLADS 0.58、BLEED 0.65。预测输血时Oakland评分AUROC为0.99(95%CI 0.98-1.00),NOBLADS为0.88(95%CI 0.85-0.90);预测止血时Strate评分AUROC为0.82(95%CI 0.79-0.85),优于Oakland 0.36和NOBLADS 0.24。作者认为这些评分可用于预测下消化道出血结局并指导临床。

要点

  • 预测大出血:Oakland评分AUROC 0.93(95%CI 0.90-0.95),高于Strate 0.73、BLEED 0.65、NOBLADS 0.58。
  • 预测安全出院:Oakland评分AUROC 0.86(95%CI 0.82-0.88)。
  • 预测输血需求:Oakland评分AUROC 0.99(95%CI 0.98-1.00),NOBLADS评分AUROC 0.88(95%CI 0.85-0.90)。
  • 预测止血需求:Strate评分AUROC 0.82(95%CI 0.79-0.85),Oakland评分0.36(95%CI 0.32-0.40),NOBLADS评分0.24(95%CI 0.20-0.28)。
  • 作者认为这些评分可用于预测下消化道出血结局并据此指导临床诊疗。

适用人群与场景

  • 纳入:推导或验证下消化道出血风险评分以预测临床结局的观察性研究和干预性研究。
  • 排除:包含16岁以下患者的研究、仅限于特定患者人群的研究、仅限于特定出血病因的研究;排除非英语文献。

诊断标准与关键阈值

  • NOBLADS评分组成:非甾体抗炎药使用、无腹泻、无腹部压痛、血压≤100 mm Hg、抗血小板药使用(非阿司匹林)、白蛋白<3.0 g/dL、疾病评分≥2(根据Charlson合并症指数)、晕厥。
  • BLEED评分组成:持续出血、低收缩压、凝血酶原时间延长、精神状态异常、合并疾病不稳定。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析;共识别3268条文献,最终纳入9项研究、12个独立队列、4种风险评分(Oakland、Strate、NOBLADS、BLEED)。
  • 预测安全出院:Oakland评分AUROC 0.86(95%CI 0.82-0.88)。
  • 预测大出血:Oakland评分AUROC 0.93(95%CI 0.90-0.95),Strate评分0.73(95%CI 0.69-0.77),NOBLADS评分0.58(95%CI 0.53-0.62),BLEED评分0.65(95%CI 0.61-0.69)。
  • 预测输血:Oakland评分AUROC 0.99(95%CI 0.98-1.00),NOBLADS评分0.88(95%CI 0.85-0.90)。
  • 预测止血:Oakland评分AUROC 0.36(95%CI 0.32-0.40),Strate评分0.82(95%CI 0.79-0.85),NOBLADS评分0.24(95%CI 0.20-0.28)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,采用随机效应模型合并数据,数据提取遵循PRISMA指南并由2名研究者独立完成,分歧经共识解决。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,这些评分可用于预测下消化道出血的结局并据此指导临床诊疗。
  • 对于预测安全出院、大出血和输血需求,Oakland评分是区分度最佳的下消化道出血风险评分;对于预测止血需求,Strate评分最佳。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Clinical prediction models, or risk scores, can be used to risk stratify patients with lower gastrointestinal bleeding (LGIB), although the most discriminative score is unknown.

OBJECTIVE: To identify all LGIB risk scores available and compare their prognostic performance.

DATA SOURCES: A systematic search of Ovid MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from January 1, 1990, through August 31, 2021, was conducted. Non-English-language articles were excluded.

STUDY SELECTION: Observational and interventional studies deriving or validating an LGIB risk score for the prediction of a clinical outcome were included. Studies including patients younger than 16 years or limited to a specific patient population or a specific cause of bleeding were excluded. Two investigators independently screened the studies, and disagreements were resolved by consensus.

DATA EXTRACTION AND SYNTHESIS: Data were abstracted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline independently by 2 investigators and pooled using random-effects models.

MAIN OUTCOMES AND MEASURES: Summary diagnostic performance measures (sensitivity, specificity, and area under the receiver operating characteristic curve [AUROC]) determined a priori were calculated for each risk score and outcome combination.

RESULTS: A total of 3268 citations were identified, of which 9 studies encompassing 12 independent cohorts and 4 risk scores (Oakland, Strate, NOBLADS [nonsteroidal anti-inflammatory drug use, no diarrhea, no abdominal tenderness, blood pressure ≤100 mm Hg, antiplatelet drug use (nonaspirin), albumin <3.0 g/dL, disease score ≥2 (according to the Charlson Comorbidity Index), and syncope], and BLEED [ongoing bleeding, low systolic blood pressure, elevated prothrombin time, erratic mental status, and unstable comorbid disease]) were included in the meta-analysis. For the prediction of safe discharge, the AUROC for the Oakland score was 0.86 (95% CI, 0.82-0.88). For major bleeding, the AUROC was 0.93 (95% CI, 0.90-0.95) for the Oakland score, 0.73 (95% CI, 0.69-0.77) for the Strate score, 0.58 (95% CI, 0.53-0.62) for the NOBLADS score, and 0.65 (95% CI, 0.61-0.69) for the BLEED score. For transfusion, the AUROC was 0.99 (95% CI, 0.98-1.00) for the Oakland score and 0.88 (95% CI, 0.85-0.90) for the NOBLADS score. For hemostasis, the AUROC was 0.36 (95% CI, 0.32-0.40) for the Oakland score, 0.82 (95% CI, 0.79-0.85) for the Strate score, and 0.24 (95% CI, 0.20-0.28) for the NOBLADS score.

CONCLUSIONS AND RELEVANCE: The Oakland score was the most discriminative LGIB risk score for predicting safe discharge, major bleeding, and need for transfusion, whereas the Strate score was best for predicting need for hemostasis. This study suggests that these scores can be used to predict outcomes from LGIB and guide clinical care accordingly.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Almaghrabi M, Gandhi M, Guizzetti L, et al. Comparison of Risk Scores for Lower Gastrointestinal Bleeding: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022. PMID: 35622365. doi:10.1001/jamanetworkopen.2022.14253

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。